These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 25244440

  • 1. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.
    PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
    Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.
    Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [Abstract] [Full Text] [Related]

  • 11. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ.
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [Abstract] [Full Text] [Related]

  • 12. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.
    PLoS One; 2013 Dec; 8(11):e78897. PubMed ID: 24244383
    [Abstract] [Full Text] [Related]

  • 13. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
    Wang L, Gao L, Xu S, Gong S, Chen L, Lü S, Chen J, Qiu H, Xu X, Ni X, Song X, Zhang W, Yang J, Liu M, Hu X, Wang J.
    J Hematol Oncol; 2013 Nov 07; 6(1):85. PubMed ID: 24517186
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
    Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P.
    Oncotarget; 2012 Dec 07; 3(12):1588-99. PubMed ID: 23249862
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
    Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Larochelle A, Melenhorst JJ.
    Stem Cell Res; 2015 Jan 07; 14(1):95-104. PubMed ID: 25535865
    [Abstract] [Full Text] [Related]

  • 20. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P.
    Haematologica; 2012 Feb 07; 97(2):219-26. PubMed ID: 21993666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.